Boehringer Ingelheim rolls out the red carpet for Hollywood

Boehringer Ingelheim has appointed a new General Manager for its Australia and New Zealand (ANZ) operations, with Ed Hollywood set to take the helm on 1 March. He will succeed Dirk Otto who was promoted to Head of Strategy & Development for Boehringer globally.

A seasoned and growth-focused leader, Hollywood brings nearly 13 years of experience with Boehringer Ingelheim, having held increasingly senior roles across the company’s headquarters in Germany, as well as in Canada and France.

Most recently, Hollywood served as Head of Human Pharmaceuticals for Boehringer France, where he achieved consistent year-on-year growth over the past five years. During this time, he also contributed to the broader pharmaceutical industry as a Board member of The French Pharmaceutical Companies Association, LEEM (Les Entreprises du Médicament).

“I am excited to take the reins of a business primed for long-term success, having gone from strength to strength in both Animal and Human Health on both sides of the Tasman,” Hollywood said. “As Australia and New Zealand embark on long-awaited healthcare system reform, there are boundless opportunities to make a positive societal and economic impact through medical innovation and improvement.”

Hollywood is no stranger to the ANZ market. In 2018-19, while serving as Corporate Regional Business Manager at Boehringer Ingelheim’s global headquarters in Ingelheim, he worked closely with the ANZ Leadership Team to support financial and strategic objectives.

His career in the pharmaceutical industry began before joining Boehringer in 2012, with roles at Bristol-Myers Squibb (BMS) and Wyeth in product management, sales, and marketing across France and the United Kingdom. Born, raised, and educated in Scotland, Hollywood credits his international experience for shaping his leadership approach.

“I am grateful to Dirk for leaving our ANZ business on such strong footing, and I share his passion for people development and capability building,” Hollywood said.

During Otto’s tenure, Boehringer ANZ bolstered its leadership in animal health while expanding its human health portfolio with the launch of new medicines and indications addressing critical areas such as heart failure, chronic kidney disease, and childhood type 2 diabetes.

The company’s commitment to its people has been reaffirmed by The Top Employers Institute, which named Boehringer Ingelheim a ‘Global Top Employer’ for the fifth consecutive year. The company is one of 17 organisations worldwide to achieve this accolade.

“This recognition is testament to Boehringer’s sustained efforts to nurture and grow our people as the backbone of our company and the driving force behind our success,” said Lisa Price, Head of Human Resources for Boehringer Ingelheim ANZ.

“We will work in unison with Ed to further advance talent and career development programs that make Boehringer an employer of choice in Australia and New Zealand,” she remarked.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.